Matinas Biopharma Holdings PE Ratio 2012-2019 | MTNB

Current and historical p/e ratio for Matinas Biopharma Holdings (MTNB) from 2012 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Matinas Biopharma Holdings PE ratio as of July 19, 2019 is 0.00.
Matinas Biopharma Holdings PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-07-19 0.72 0.00
2019-03-31 1.09 $-0.14 0.00
2018-12-31 0.60 $-0.15 0.00
2018-09-30 0.92 $-0.15 0.00
2018-06-30 0.43 $-0.16 0.00
2018-03-31 0.76 $-0.16 0.00
2017-12-31 1.16 $-0.36 0.00
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.103B $0.000B
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $54.610B 34.89
Astellas Pharma (ALPMY) Japan $28.433B 13.94
Takeda Pharmaceutical (TAK) Japan $27.154B 7.97
UCB SA (UCBJF) Belgium $15.866B 0.00
Eisai (ESALY) Japan $15.807B 27.18
Grifols, S.A (GRFS) Spain $15.209B 19.23
Merck (MKGAF) Germany $13.448B 18.35
IPSEN SA ADR (IPSEY) France $10.783B 0.00
Ionis Pharmaceuticals (IONS) United States $9.649B 21.09
Sage Therapeutics (SAGE) United States $9.439B 0.00
Ono Pharmaceutical (OPHLF) Japan $9.254B 19.78
Catalent (CTLT) United States $7.912B 31.75
Neurocrine Biosciences (NBIX) United States $7.824B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.738B 10.61
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.257B 19.83
STADA ARZNEIMI (STDAF) Germany $5.634B 0.00
Nektar Therapeutics (NKTR) United States $5.573B 9.08
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.420B 0.00
Orion OYJ (ORINY) Finland $5.275B 27.16
Hypermarcas (HYPMY) Brazil $4.805B 16.89
Evotec AG (EVTCY) Germany $4.267B 45.80
Tilray (TLRY) Canada $4.238B 0.00
FibroGen (FGEN) United States $3.983B 0.00
United Therapeutics (UTHR) United States $3.300B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.220B 11.56
Arrowhead Pharmaceuticals (ARWR) United States $2.766B 416.71
PTC Therapeutics (PTCT) United States $2.514B 0.00
Xencor (XNCR) United States $2.513B 68.60
Zogenix (ZGNX) United States $2.035B 0.00
Portola Pharmaceuticals (PTLA) United States $1.814B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.658B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.647B 79.76
Enanta Pharmaceuticals (ENTA) United States $1.613B 22.04
CLINIGEN GP (CLIGF) United Kingdom $1.577B 0.00
USANA Health Sciences (USNA) United States $1.462B 12.71
Heron Therapeutics (HRTX) United States $1.461B 0.00
Corcept Therapeutics (CORT) United States $1.263B 18.03
ArQule (ARQL) United States $1.158B 0.00
Aerie Pharmaceuticals (AERI) United States $1.062B 0.00
Radius Health (RDUS) United States $1.035B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.016B 3.66
Theravance Biopharma (TBPH) Cayman Islands $0.986B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.879B 0.00
Endo (ENDP) Ireland $0.740B 1.19
Concordia (CXRXF) Canada $0.716B 0.00
Aptorum Group (APM) China $0.636B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.577B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.574B 0.00
Organogenesis Holdings (ORGO) United States $0.562B 0.00
TherapeuticsMD (TXMD) United States $0.543B 0.00
Karyopharm Therapeutics (KPTI) United States $0.505B 0.00
GlycoMimetics (GLYC) United States $0.482B 0.00
ChemoCentryx (CCXI) United States $0.474B 0.00
Translate Bio (TBIO) United States $0.472B 0.00
Akebia Therapeutics (AKBA) United States $0.457B 0.00
Dova Pharmaceuticals (DOVA) United States $0.452B 0.00
Dermira (DERM) United States $0.450B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.444B 22.38
Siga Technologies (SIGA) United States $0.440B 1.04
Catalyst Pharmaceuticals (CPRX) United States $0.417B 0.00
CV Sciences (CVSI) United States $0.413B 0.00
Flexion Therapeutics (FLXN) United States $0.412B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.403B 0.00
CannTrust Holdings (CTST) Canada $0.391B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.390B 0.00
Indivior (INVVY) United States $0.386B 1.39
BioCryst Pharmaceuticals (BCRX) United States $0.374B 0.00
Innate Pharma SA (IPHYF) France $0.364B 0.00
Harpoon Therapeutics (HARP) United States $0.348B 0.00
ImmunoGen (IMGN) United States $0.348B 0.00
Collegium Pharmaceutical (COLL) United States $0.346B 0.00
Xeris Pharmaceuticals (XERS) United States $0.331B 0.00
KalVista Pharmaceuticals (KALV) United States $0.305B 0.00
Rafael Holdings (RFL) United States $0.291B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.288B 0.00
Molecular Templates (MTEM) United States $0.272B 0.00
Concert Pharmaceuticals (CNCE) United States $0.256B 0.00
OptiNose (OPTN) United States $0.250B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.236B 0.00
Lannett Co Inc (LCI) United States $0.235B 2.28
Recro Pharma (REPH) United States $0.220B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.215B 0.00
Ocular Therapeutix (OCUL) United States $0.195B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.193B 0.00
Redhill Biopharma (RDHL) Israel $0.178B 0.00
Nature's Sunshine Products (NATR) United States $0.175B 56.63
Taiwan Liposome (TLC) Taiwan $0.163B 0.00
Calithera Biosciences (CALA) United States $0.162B 0.00
Ardelyx (ARDX) United States $0.157B 0.00
IMV INC (IMV) Canada $0.152B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.151B 0.00
Jounce Therapeutics (JNCE) United States $0.136B 0.00
Majesco Entertainment (PTE) United States $0.132B 0.00
MEI Pharma (MEIP) United States $0.131B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.131B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.126B 0.00
DURECT (DRRX) United States $0.118B 0.00
Generex Biotechnology (GNBT) United States $0.107B 0.00
AgeX Therapeutics (AGE) United States $0.106B 0.00
Aquestive Therapeutics (AQST) United States $0.103B 0.00
MediWound (MDWD) Israel $0.101B 0.00
RENEURON GP (RNUGF) United Kingdom $0.100B 0.00
Iterum Therapeutics (ITRM) Ireland $0.093B 0.00
Infinity Pharmaceuticals (INFI) United States $0.092B 0.00
Mast Therapeutics (SVRA) United States $0.089B 0.00
Champions Oncology (CSBR) United States $0.089B 768.00
Genocea Biosciences (GNCA) United States $0.089B 0.00
Capnia (SLNO) United States $0.088B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.088B 63.00
Nivalis Therapeutics (ALPN) United States $0.088B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.086B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.083B 0.00
Aclaris Therapeutics (ACRS) United States $0.082B 0.00
Cardiome Pharma (CORV) Canada $0.080B 0.00
Natural Alternatives (NAII) United States $0.079B 7.90
Otonomy (OTIC) United States $0.077B 0.00
China SXT Pharmaceuticals (SXTC) China $0.075B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.074B 0.00
Novan (NOVN) United States $0.070B 0.00
Neos Therapeutics (NEOS) United States $0.070B 0.00
Pharmaxis (PXSLY) Australia $0.067B 0.00
SCYNEXIS (SCYX) United States $0.066B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.055B 0.00
India Globalization Capital (IGC) United States $0.055B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.055B 0.00
Medicure (MCUJF) Canada $0.053B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.051B 0.00